Multiple media reports say that Danaher (DHR) is nearing a deal to buy medical device firm Masimo (MASI) for $9.9 billion U.S.
Based in California, Masimo develops patient monitoring and sensor devices.
However, the company is best known for its yearslong battle with Apple (AAPL) over whether the iPhone maker has infringed on the company’s blood-oxygen sensor patents.
Masimo and Apple continue to battle in court to this day.
Danaher is a much larger medical device and healthcare technology company. Its products serve the biotechnology, life sciences, and diagnostic industries.
Danaher has a history of growing through mergers and acquisitions. The company is expected to pay $180 U.S. per share in cash for Masimo, though a deal has not yet been announced.
Masimo recently reported that its 2025 revenue came to $1.52 billion U.S., up 9% from the previous year.
MASI stock is up 34% on reports the company is about to be acquired. Prior to today (Feb. 17), Masimo’s share price had declined 28% over the last 12 months to $130.15 U.S.
DHR stock is down 7% on news of the Masimo acquisition. Danaher’s share price has risen 4% in the last 12 months to $212.58 U.S.
